Company news

Ocular Therapeutix, Inc. news in 2022

Ocular Therapeutix, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences

November 7, 2022

Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update

November 6, 2022

Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results

October 23, 2022

Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

September 26, 2022

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

September 21, 2022

Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022

Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 9, 2022

Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update

August 7, 2022

Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results

July 24, 2022

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

June 7, 2022

Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference

May 31, 2022

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

May 8, 2022

Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

May 2, 2022

Ocular Therapeutix™ to Report First Quarter 2022 Financial Results

April 25, 2022

Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 24, 2022

Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 13, 2022

Ocular Therapeutix™ to Present at the Cowen 42nd Annual Healthcare Conference

March 3, 2022

Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update

February 27, 2022

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

February 21, 2022

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

February 10, 2022

AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients

January 17, 2022

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

January 3, 2022

Calls in 2022

Decks in 2022